Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance therapy after R0 resection for oligorecurrent ovarian cancer previously on PARP inhibitor
ChiCTR2600116607Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer and fallopian tube cancer (PFTC) comparing Iparomlimab + Tuvonralimab + PARP inhibitor + bevacizumab with PARP inhibitor + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2600116607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116607.